BioChaperone insulin combo: Final Phase I/II data

Final data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that a single 0.8 IU/kg dose of BioChaperone Combo had a faster onset of action, defined as time to a >=5% reduction in glucose from baseline, vs. a single 0.8 IU/kg dose of Humalog Mix 75/25 insulin lispro protamine/insulin lispro (25 vs. 40 minutes, p=0.002). Additionally, 17 of 19 patients treated with BioChaperone Combo were still under glucose control at 30 hours post-administration vs. 6 of 20 patients treated with Humalog Mix (p=0.0002). BioChaperone Combo was well tolerated and did not induce any local reactions. Adocia previously reported data that BioChaperone Combo had a 30% faster onset of action vs. Humalog Mix (see BioCentury, March 3). ...